NuGen Announces Voting Results of Annual and Special Meeting
NuGen Medical Devices Inc. (TSXV: NGMD) held its annual and special meeting on August 20, 2024, with shareholders voting in favor of all resolutions. Key outcomes include:
1. Election of all nominated directors with over 99% approval for each.
2. Appointment of KPMG LLP as auditors with 99.99% approval.
3. Approval of the company's stock option plan with 99.86% support.
The company will hold a separate special shareholder meeting to seek approval for Sol-Millennium Medical HK and Nature Health Development (Hong Kong) Co., as control persons. NuGen, a developer of needle-free subcutaneous therapeutic administration devices, will provide further details on this meeting in due course.
NuGen Medical Devices Inc. (TSXV: NGMD) ha tenuto la sua riunione annuale e straordinaria il 20 agosto 2024, con gli azionisti che hanno votato a favore di tutte le risoluzioni. I risultati chiave includono:
1. Elezione di tutti i direttori nominati con oltre il 99% di approvazione per ciascuno.
2. Nomina di KPMG LLP come revisori contabili con un'approvazione del 99,99%.
3. Approvazione del piano di opzioni azionarie dell'azienda con un supporto del 99,86%.
L'azienda terrà una riunione straordinaria separata degli azionisti per cercare l'approvazione di Sol-Millennium Medical HK e Nature Health Development (Hong Kong) Co., come persone di controllo. NuGen, sviluppatore di dispositivi terapeutici a somministrazione sottocutanea senza aghi, fornirà ulteriori dettagli su questa riunione a tempo debito.
NuGen Medical Devices Inc. (TSXV: NGMD) celebró su reunión anual y extraordinaria el 20 de agosto de 2024, con los accionistas votando a favor de todas las resoluciones. Los resultados clave incluyen:
1. Elección de todos los directores nominados con más del 99% de aprobación para cada uno.
2. Nombramiento de KPMG LLP como auditores con un 99.99% de aprobación.
3. Aprobación del plan de opciones sobre acciones de la empresa con un apoyo del 99.86%.
La empresa realizará una reunión especial de accionistas separada para buscar la aprobación de Sol-Millennium Medical HK y Nature Health Development (Hong Kong) Co., como personas de control. NuGen, desarrollador de dispositivos de administración terapéutica subcutánea sin aguja, proporcionará más detalles sobre esta reunión en su debido momento.
NuGen Medical Devices Inc. (TSXV: NGMD)는 2024년 8월 20일 연례 및 특별 총회를 개최하였고, 주주들은 모든 결의안에 찬성 투표를 하였습니다. 주요 결과는 다음과 같습니다:
1. 모든 지명 이사의 선출로, 각 이사에 대한 승인률이 99%를 초과합니다.
2. 감사인으로 KPMG LLP의 임명이 99.99%의 승인률을 기록했습니다.
3. 회사의 스톡옵션 계획이 99.86%의 지지를 얻어 승인되었습니다.
회사는 Sol-Millennium Medical HK와 Nature Health Development (Hong Kong) Co.를 관리자로 승인받기 위해 별도의 특별 주주 총회를 개최할 예정입니다. 주사기를 사용하지 않는 피하 치료 배출장치의 개발자인 NuGen은 이 회의에 대한 추가 세부사항을 곧 제공할 것입니다.
NuGen Medical Devices Inc. (TSXV: NGMD) a tenu son assemblée générale annuelle et extraordinaire le 20 août 2024, les actionnaires ayant voté en faveur de toutes les résolutions. Les résultats clés incluent :
1. Élection de tous les administrateurs nommés avec plus de 99% d'approbation pour chacun.
2. Nommer KPMG LLP comme auditeurs avec 99,99% d'approbation.
3. Approbation du plan d'options d'achat d'actions de la société avec un soutien de 99,86%.
L'entreprise tiendra une assemblée spéciale séparée des actionnaires pour demander l'approbation de Sol-Millennium Medical HK et de Nature Health Development (Hong Kong) Co., en tant que personnes de contrôle. NuGen, développant des dispositifs thérapeutiques d'administration sous-cutanée sans aiguille, fournira plus de détails sur cette réunion en temps voulu.
NuGen Medical Devices Inc. (TSXV: NGMD) hat am 20. August 2024 seine jährliche und besondere Hauptversammlung abgehalten, bei der die Aktionäre allen Beschlüssen zugestimmt haben. Wichtige Ergebnisse sind:
1. Wahl aller nominierten Direktoren mit über 99% Zustimmung für jeden.
2. Ernennung von KPMG LLP als Wirtschaftsprüfer mit 99,99% Zustimmung.
3. Genehmigung des Aktienoptionsplans des Unternehmens mit 99,86% Unterstützung.
Das Unternehmen wird eine separate außerordentliche Hauptversammlung abhalten, um die Genehmigung von Sol-Millennium Medical HK und Nature Health Development (Hong Kong) Co. als Kontrollpersonen zu beantragen. NuGen, Entwickler von nadelfreien subkutanen Therapiedispositiven, wird zu gegebener Zeit weitere Details zu dieser Sitzung bekannt geben.
- High shareholder approval rates (over 99%) for all resolutions
- Successful election of all nominated directors
- Approval of stock option plan with 99.86% support
- None.
Toronto, Ontario--(Newsfile Corp. - August 21, 2024) - NuGen Medical Devices Inc. (TSXV: NGMD) (the "Company" or "NuGen") a leading developer of needle-free devices to administer therapeutics subcutaneously, is pleased to announce voting results from the annual and special meeting of the Company's shareholders (the "Meeting") held on August 20, 2024. At the Meeting, shareholders voted in favour of all resolutions brought before them. Details of all resolutions that were voted upon are set out in the Management Information Circular (the "Management Information Circular") dated July 22, 2024. The Management Information Circular is available on SEDAR+ (www.sedarplus.ca).
Election of Directors
All of the board of director nominees listed in the Management Information Circular were elected as directors of the Company. Results of the vote were as follows:
| Nominee | Votes For |
| Richard Buzbuzian | |
| Tony Di Benedetto | |
| Karen Dunlap | |
| John Leombruno | |
| Philip Cortese | |
| Chris Irwin |
Other Items of Business
In addition, at the Meeting, shareholders approved the appointment of the Company's auditors, KPMG LLP, and the annual approval and confirmation of the company's stock option plan. The results of the votes were as follows:
| Item | Votes For |
| Appointment of KPMG LLP as auditors of the Company | |
| Approval of Stock Option Plan |
As noted in the Company's press release dated August 15, 2024, the Company will seek the approval of its shareholders for the creation of Sol-Millennium Medical HK Limited and Nature Health Development (Hong Kong) Co., Limited as control persons of the Company at a special shareholder meeting to be held at a later date. The Company will update the market with the details of such meeting at the appropriate time.
About NuGen
NuGen is a leading developer of needle-free devices to administer therapeutics subcutaneously. The Company is marketing and selling its next-generation InsuJet™ needle-free injection system designed to improve the lives of millions of diabetics. InsuJet™ is approved for sale in 42 countries around the world.
For further information, please visit:
Websites: www.insujet.com, www.nugenmd.com, www.solm.com, and www.solm.com/insujet/
Instagram: @NuGenMD
Twitter: @NuGenMD
LinkedIn: https://www.linkedin.com/company/nugenmd/
and www.linkedin.com/company/sol-millennium-medical-group/
For further information, please contact:
Tony Di Benedetto
Executive Chairman
(416) 791-9399
tony@nugenmd.com
Ian Heynen
CEO
(416) 560-1019
ian@nugenmd.com
To arrange a media interview with NuGen, please contact:
Morna Gorman
(416) 553-1732
morna@nugenmd.com
Notice Regarding Forward-Looking Information:
Neither TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accept responsibility for the adequacy or accuracy of this release.
This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking statements") within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as "expects", or "does not expect", "is expected", "anticipates" or "does not anticipate", "plans", "budget", "scheduled", "forecasts", "estimates", "believes" or "intends" or variations of such words and phrases or stating that certain actions, events or results "may" or "could", "would", "might" or "will" be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. These forward-looking statements are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking information. The forward-looking information contained herein is given as of the date hereof and the Company assumes no responsibility to update or revise such information to reflect new events or circumstances, except as required by law.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/220605
FAQ
What were the voting results for NuGen Medical Devices' (TSXV: NGMD) annual and special meeting on August 20, 2024?
Who were the directors elected to NuGen Medical Devices' (TSXV: NGMD) board in the August 20, 2024 meeting?
What additional approval is NuGen Medical Devices (TSXV: NGMD) seeking from shareholders in a future special meeting?
